UK markets closed

Orion Oyj (ORINF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
47.160.00 (0.00%)
At close: 12:14PM EDT

Orion Oyj

Orionintie 1A
Espoo 02200
358 10 4261

IndustryDrug Manufacturers - General
Full-time employees3,632

Key executives

NameTitlePayExercisedYear born
Dr. Liisa HurmePresident, CEO & Chairman of Executive Management Board820.63kN/A1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)CFO & Member of the Executive Management BoardN/AN/A1961
Mr. Olli Huotari Ll.M.Senior VP of Corporate Functions, General Counsel, Secretary & Member of Executive Management BoardN/AN/A1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)Senior VP of Generics and Consumer Health Business Division & Member of the Exe. Mgmt. BoardN/AN/A1966
Prof. Outi Vaarala M.D., Ph.D.Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. BoardN/AN/A1962
Mr. Juhani KankaanpaaSenior VP of Global Operations & Member of Executive Management BoardN/AN/AN/A
Mr. Niclas Lindstedt EMBA, M.Sc.Senior VP of Animal Health Business Division & Member of the Exe. Mgmt. BoardN/AN/AN/A
Mr. Hao Pan M.Sc.Senior VP of the Branded Products Business Division & Member of the Exe. Mgmt. BoardN/AN/A1971
Ms. Julia Irene MachareySenior Vice President of People & Culture and Member of Management BoardN/AN/A1977
Mr. Rene Lindell M.Sc., Ph.D.Member of Group Executive Management BoardN/AN/A1976
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Corporate governance

Orion Oyj’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 10; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.